Should we treat mild subclinical/mild hyperthyroidism? No

Area of Science:

• Endocrinology
• Thyroidology

Background:

• Subclinical hyperthyroidism, characterized by suppressed TSH with normal thyroid hormones, affects ~3% of the population.
• Prevalence is higher in older adults and iodine-deficient regions; 50% may be on levothyroxine.
• Causes include Graves' disease, toxic nodular goiter, and thyroiditis; non-thyroidal illness can cause false positives.

Purpose of the Study:

• To review the controversial management of subclinical hyperthyroidism.
• To evaluate the evidence for and against intervention in mild thyroid over-activity.
• To discuss the risks and benefits of treatment versus a watchful waiting approach.

Main Methods:

• Literature review of epidemiological studies and clinical trials.
• Analysis of data regarding the progression of subclinical to overt hyperthyroidism.
• Assessment of potential outcomes associated with intervention versus non-intervention.

Main Results:

• Conversion to overt hyperthyroidism occurs in up to 5% per year for undetectable TSH levels.
• Evidence supporting improved outcomes (mortality, atrial fibrillation, fractures) with intervention is sparse.
• No large-scale, randomized controlled trials on subclinical hyperthyroidism intervention exist.

Conclusions:

• The benefits of treating subclinical hyperthyroidism are not well-supported by current data.
• A
• wait and see
• policy may be preferable for most patients to avoid unnecessary treatment risks.
• Potential benefits must be weighed against the significant morbidity of hyperthyroid treatment.